Abeona announces closing of $103.5 million underwritten public offering and full exercise of underwriters’ option to purchase additional shares

New york and cleveland, dec. 24, 2019 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten public offering, with a gross offering size of approximately $103.5 million, which includes the full exercise of the underwriters’ option to purchase 5,400,000 additional shares of common stock, at a public offering price of $2.50 per share. in addition, as part of the offering, abeona sold to great point partners (“gpp”), an existing investor, pre-funded warrants to purchase up to an aggregate of 9,017,055 shares of common stock at a purchase price of $2.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant.
ABEO Ratings Summary
ABEO Quant Ranking